Valitor, Inc. has successfully recruited and hired Taylor Holstlaw to join our team as a research associate. Taylor has worked for life sciences startup companies since graduating from the UC Berkeley Department of Bioengineering, and she will apply her experience in assay development and process optimization to the R&D for our multivalent protein conjugate technology.
Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised
Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammat